In vitroOATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia
Authors:
- Sonia M. de MoraisSMSonia M. de Morais
- Ryota KikuchiRKRyota Kikuchi
- Richard L. VoormanRVRichard L. Voorman
- Xiaofeng LiXLXiaofeng Li
- Daniel A. J. BowDBDaniel A. J. Bow
- 25 July 2013
- journal article
- Published by Taylor & Francis in Xenobiotica
- Vol. 44 (3) , 276-282
Abstract
1. Transient benign unconjugated hyperbilirubinemia has been observed clinically with several drugs including indinavir, cyclosporine, and rifamycin SV. Genome-wide association studies have shown significant association of OATP1B1 and UGT1A1 with elevations of unconjugated bilirubin, and OATP1B1 inhibition data correlated with clinical unconjugated hyperbilirubinemia for several compounds. 2. In this study, inhibition of OATP1B3 and UGT1A1, in addition to OATP1B1, was explored to determine whether one measure offers value over the other as a potential prospective tool to predict unconjugated hyperbilirubinemia. OATP1B1 and OATP1B3-mediated transport of bilirubin was confirmed and inhibition was determined for atazanavir, rifampicin, indinavir, amprenavir, cyclosporine, rifamycin SV and saquinavir. To investigate the intrinsic inhibition by the drugs, both in vivo Fi (fraction of intrinsic inhibition) and R-value (estimated maximum in vivo inhibition) for OATP1B1, OATP1B3 and UGT1A1 were calculated. 3. The results indicated that in vivo Fi values >0.2 or R-values >1.5 for OATP1B1 or OATP1B3, but not UGT1A1, are associated with previously reported clinical cases of drug-induced unconjugated hyperbilirubinemia. 4. In conclusion, inhibition of OATP1B1 and/or OATP1B3 along with predicted human pharmacokinetic data could be used pre-clinically to predict potential drug-induced benign unconjugated hyperbilirubinemia in the clinic.Keywords
This publication has 37 references indexed in Scilit:
- Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liverJournal of Clinical Investigation, 2012
- Systemic Absorption of Rifamycin SV MMX Administered as Modified-Release Tablets in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2011
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Influence of Alpha-1 Glycoprotein Acid Concentrations and Variants on Atazanavir Pharmacokinetics in HIV-Infected Patients Included in the ANRS 107 TrialAntimicrobial Agents and Chemotherapy, 2010
- Incidence of Atazanavir-associated Hyperbilirubinemia in Korean HIV Patients: 30 Months Follow-up Results in a Population with Low UDP-glucuronosyltransferase1A1*28 Allele FrequencyJournal of Korean Medical Science, 2010
- Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemiaHuman Molecular Genetics, 2009
- Genome-wide association meta-analysis for total serum bilirubin levelsHuman Molecular Genetics, 2009
- Compartmental Pharmacokinetic Analysis of Oral Amprenavir with Secondary PeaksAntimicrobial Agents and Chemotherapy, 2007
- Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemiaChemico-Biological Interactions, 2004
- SaquinavirClinical Pharmacokinetics, 1998